• Press Release

Mount Sinai’s Cancer Science in the Spotlight at 2025 ASCO

Building exterior
  • New York, NY
  • (May 29, 2025)

The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai is proud to announce its robust presence at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place this week in Chicago. With more than 15 presentations, including oral abstracts, poster sessions, and collaborative studies across multiple disciplines, Mount Sinai investigators are contributing vital insights that are shaping the future of cancer care. 

“Our experts continue to lead the way in addressing some of the most urgent challenges in oncology, from novel therapeutics and immunotherapy to cancer care delivery and health equity,” said Ramon E. Parsons, MD, PhD, Director of The Tisch Cancer Institute and Dean for Cancer Research at the Icahn School of Medicine at Mount Sinai. “The volume and depth of our contributions to ASCO this year reflect our relentless commitment to improving cancer outcomes through research, innovation, and collaboration. Our investigators are not only advancing science—they are advancing hope for patients everywhere.” 

Notable oral presentations and posters from Mount Sinai faculty at the 2025 ASCO Annual Meeting: 

IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF). 

John Mascarenhas, MD 
Rapid Oral Abstract Session
Abstract #6515 

Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM) 

Sundar Jagannath, MD 
Oral Abstract Session 
Abstract # 7507 

A phase 1b study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable NSCLC. 

Fionnuala Crowley, MBBS 
Abstract #TPS2696  

A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer. 

Melanie Kier, MD 
Abstract # TPS5623 
Poster Bd #518b  

Unveiling drivers of MHC repression and therapeutic strategies to counter immune evasion in small cell lung cancer. 

Triparna Sen, PhD 
Abstract #8091 
Poster Bd #212  

Evaluating palliative care needs of early-phase clinical trial patients. 

Fionnuala Crowley, MBBS 
Abstract #12086 
Poster Bd #106 

Shared decision-making in follow-up care for lung cancer screening. 

Nihal Mohamed, PhD 
Abstract #12114 
Poster Bd #134 

Demographic and clinical factors associated with young-onset rectal cancer: Is the Latinx population at higher risk? 

Antoine Jeri-Yabar, MD 
Abstract #11038 
Poster Bd #377 

Global cervical cancer outcomes and national cancer system characteristics.

Erin Jay Feliciano, MD, MBA 
Abstract #5535 
Poster Bd #433 

Impact of incretin mimetic therapy on weight change in patients with cancer: A pan-cancer analysis from a single institutional cohort. 

Yan Leyfman, MD 
Abstract #10598 
Poster Bd #323

Evaluation of surrogate endpoints in muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis. 

Matthew Galsky, MD 
Abstract #4580 
Poster Bd #380

Triplet versus doublet therapy in older patients with metastatic hormone-sensitive prostate cancer: A network meta-analysis. 

Susu Zhou, MD 
Abstract #5088 
Poster Bd #287

Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial. 

John Sfakianos, MD 
Abstract #4597 
Poster Bd #397  

Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors. 

Thomas Marron, MD, PhD 
Abstract #2577 
Poster Bd #224  

IMpactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or refractory (R/R) to Janus kinase inhibitors (JAKi). 

John Mascarenhas, MD 
Abstract #TPS6588 
Poster Bd #200a

Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). 

Sundar Jagannath, MD 
Abstract #7531 
Poster Bd #99 

Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study. 

Larysa Sanchez, MD 
Abstract #TPS7565 
Poster Bd #132a 

For more information about the 2025 ASCO annual meeting visit https://www.asco.org/annual-meeting 

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.